US FDA approves Merck's RSV antibody for infants

The FDA has approved Merck's Enflonsia (clesrovimab), a monoclonal antibody, for preventing RSV in infants up to one year old. This approval provides an alternative to Sanofi and AstraZeneca's Beyfortus, which has faced supply constraints, and is expected to be available for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices will convene this month to discuss recommendations for Enflonsia's use.

Analysis

The U.S. FDA's approval of Merck's respiratory syncytial virus (RSV) antibody, Enflonsia (clesrovimab), for infants up to one year old marks a significant development in the pediatric infectious disease landscape and a positive catalyst for Merck (MRK.N), reflected in its ticker-specific sentiment score of 0.8. This approval positions Enflonsia as an alternative to Sanofi (SASY.PA) and AstraZeneca's (AZN.L) Beyfortus, which has faced notable supply constraints, indicating an unmet demand in the market for RSV prevention in infants. Enflonsia, a single-dose monoclonal antibody, is designed to protect infants during their first RSV season, a period when RSV poses a substantial risk, leading to an estimated 58,000–80,000 hospitalizations annually in the U.S. for children under five. The product's expected availability for the 2025-2026 RSV season means near-term revenue impact is delayed, but the upcoming CDC's Advisory Committee on Immunization Practices meeting to discuss usage recommendations will be a key milestone for its potential adoption. While the introduction of Enflonsia will eventually intensify competition for Sanofi and AstraZeneca, the current supply shortages for Beyfortus and Enflonsia's phased launch suggest the market may initially accommodate new entrants, consistent with the neutral sentiment observed for Sanofi and AstraZeneca in response to this specific news.

Key Decisions for Investors

• Investors should view this FDA approval as a positive long-term development for Merck, anticipating a new revenue stream from Enflonsia commencing with the 2025-2026 RSV season, and closely monitor the upcoming CDC ACIP recommendations for its usage and subsequent market uptake.
• Shareholders in Sanofi and AstraZeneca should assess the potential impact on Beyfortus's market share and pricing dynamics once Merck's Enflonsia becomes commercially available, although immediate adverse effects are likely tempered by existing market supply limitations and Enflonsia's future launch date.
• The approval highlights the significant unmet medical need and substantial commercial opportunity within the infant RSV prophylaxis market, suggesting continued investor focus on companies developing solutions in this expanding therapeutic area.